Please login to the form below

Not currently logged in
Email:
Password:

Paul Navarre moves from Allergan to Ferring Pharmaceuticals

Takes up CEO role at its Ferring Holding subsidiary

Paul NavarreFerring Pharmaceuticals has appointed Paul Navarre as CEO of Ferring Holding Inc - a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharma company - in a role that will see him assume responsibility for all of the group’s activities including commercial operations, clinical development and manufacturing.

Navarre has more than 25 years’ experience in the pharmaceuticals and consumer good industries and joins from Allergan, where he was president of Allergan International and managed a $3bn speciality care business covering dermatology, ophthalmology, urology and neurosciences.

Before joining Allergan, Navarre spent 15 years at Procter & Gamble holding positions in France, USA, Switzerland, Italy and the UK.

He said: “Ferring is a fast growing pharmaceutical company with a unique culture centred on people and patients.

“I am very excited to lead this organisation into the next phase of its development.”

As CEO, Navarre will report to the board of directors chaired by Michel Pettigrew, president of the executive board and chief operating officer of Ferring Group.

Pettigrew said: “Paul’s extensive pharmaceutical speciality care experience and proven international leadership skills will help him take our successful US operations to the next level, pursuing our rapid extension.”

Navarre succeeds Aaron Graff who has been appointed to a global role as executive vice president, chief commercial officer and member of the Ferring Group executive board.

6th June 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

#DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need...
JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...